

EXPLORING THE POWER OF PREHOSPITAL DUAL SEQUENTIAL DEFIBRILLATION IN OVERCOMING REFRACTORY CARDIAC ARREST

Mirosław Dabkowski¹, Michał Pruc^{1,2}, Francesco Chirico³, Nicola Luigi Bragazzi⁴,
Lukasz Szarpak^{5–7}

¹Research Unit, Polish Society of Disaster Medicine, Warsaw, Poland

²Department of Public Health, International Academy of Ecology and Medicine, Kyiv, Ukraine

³Post-Graduate School of Occupational Health, Università Cattolica del Sacro Cuore, Rome, Italy

⁴Department of Mathematics and Statistics, Laboratory for Industrial and Applied Mathematics (LIAM), York University, Toronto, ON, Canada

⁵Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine Houston, Houston, TX, USA

⁶Institute of Outcomes Research, Maria Skłodowska-Curie Medical Academy, Warsaw, Poland

⁷Research Institute, Maria Skłodowska-Curie Białystok Oncology Center, Białystok, Poland

KEYWORDS: dual sequential defibrillation; dual sequential shock; cardiopulmonary resuscitation; cardiac arrest; out-of-hospital cardiac arrest

Disaster Emerg Med J 2023; 8(4): 263–264

To the Editor,
a significant death rate and poor neurological outcomes are linked with refractory ventricular fibrillation (VF). Because the left ventricle is a posterior structure and is located in the part of the heart farthest from the straight line between the conventional anterior-lateral electrode pads, there is a danger that it may not be properly defibrillated. This danger can be reduced by placing an electrode pad closer to the direct line between the anterior and lateral pads. Double sequential external defibrillation (DSED) may result in a higher voltage gradient and more energy provided by the second defibrillator shock across the posterior area of the left ventricle as compared to the conventional anterior-lateral pad design. This enhances the likelihood that the defibrillation will completely terminate the arrhythmia [1]. The practice of DSED has recently garnered a lot of interest as researchers

continue their search for novel approaches to the management of refractory VF. The aim of our work was to determine the effectiveness of DSED in relation to the studies conducted so far. The detailed methodology of the survey can be found in the supplementary digital file. Six studies involving a total of 1,360 patients were included in the meta-analysis (Supplementary Tab. 1) [1–6]. Considering all the research ROSC at any time among DSED and standard defibrillation was 37.0% vs. 38.0% (OR = 0.91; 95% CI: 0.46 to 1.77; p = 0.77; Supplementary Tab. 2). There were also no statistically significant differences between DSED and standard defibrillation in terms of other parameters analyzed: survival to hospital admission (35.7% vs 36.1%; OR = 1.24; 95% CI: 0.53 to 2.87; p = 0.62), survival to hospital discharge (19.9% vs 15.0%; OR = 1.12; 95% CI: 0.45 to 2.78; p = 0.80). When we restrict our analysis to include

CORRESPONDING AUTHOR:

Nicola Luigi Bragazzi, Laboratory for Industrial and Applied Mathematics (LIAM), Department of Mathematics and Statistics, York University, 4700 Keele Street, Toronto, ON M3J1P3, Canada, e-mail: robertobragazzi@gmail.com

Submitted: 13.06.2023 Accepted: 28.06.2023 Published online: 26.07.2023

This article is available in open access under Creative Commons Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

the findings of the most current study, which also occurs to be the only randomized trial — DOSE-VF, we find that the DSED had a greater survival to hospital discharge (30.4%; relative risk [RR], 2.21; 95% CI 1.33–3.67) than conventional defibrillation (13.3%). Notably, as compared to normal defibrillation, DSED (RR 2.21; 95% CI 1.26–3.88) was linked with a larger proportion of patients attaining good neurological outcomes (RR 1.48; 95% CI 0.81–2.71). Moreover, as indicated by Kim et al. [5] the use of DSED compared to standard defibrillation was associated with better neurological outcomes (CPC 1 or 2) at 12 months (29.4% vs 9.5%, respectively; OR = 3.96; 95% CI: 0.66 to 23.76; $p = 0.13$) [2]. A detailed list of the publications included in the above-pooled analyses have been presented in the Supplementary File. Taking into account all the research results so far, we should be skeptical about this topic, however, the limitations in the form of a small number of studies and patients convince us to approach the subject optimistically and continue the research due to the very good results of the DOSE-VF randomized study. DSED may prove to be the future for patients with VF and significantly improve the prognosis of this condition. Both the 2020 American Heart Association Guidelines and the International Liaison Committee on Resuscitation Consensus on Science do not currently support the use of DSED, DOSE-VF could change this approach dramatically and we believe that it should be incorporated in clinician guidelines.

Article information and declarations

Acknowledgments

Not applicable.

Conflict of interests

The authors declare no conflict of interest.

Funding

This research received no external funding.

Data availability

Data are available from the corresponding author upon reasonable request.

Institutional review board statement

Not applicable.

Informed consent statement

Not applicable.

Author contributions

Conceptualization, M.D. and F.C.; methodology, M.D.; software, M.D., L.S., and N.L.B.; validation, M.D. and L.S.; formal analysis, M.D.; investigation, M.D., L.S., M.P., and N.L.B.; resources, M.D.; data curation, M.D., M.P., and J.S.; writing — original draft preparation, M.D.; writing — review and editing, all authors; visualization, M.D.; supervision, L.S. and N.L.B.; project administration, M.D.; All authors have read and agreed to the published version of the manuscript.

Supplementary material

The Supplementary Material for this article can be found online at: https://journals.viamedica.pl/disaster_and_emergency_medicine/article/view/DEMJa2023.0027#supplementaryFiles.

REFERENCES

1. Beck LR, Ostermayer DG, Ponce JN, et al. Effectiveness of prehospital dual sequential defibrillation for refractory ventricular fibrillation and ventricular tachycardia cardiac arrest. *Prehosp Emerg Care*. 2019; 23(5): 597–602, doi: [10.1080/10903127.2019.1584256](https://doi.org/10.1080/10903127.2019.1584256), indexed in Pubmed: 30773983.
2. Cheskes S, Wudwud A, Turner L, et al. The impact of double sequential external defibrillation on termination of refractory ventricular fibrillation during out-of-hospital cardiac arrest. *Resuscitation*. 2019; 139: 275–281, doi: [10.1016/j.resuscitation.2019.04.038](https://doi.org/10.1016/j.resuscitation.2019.04.038), indexed in Pubmed: 31059670.
3. Cheskes S, Verbeek PR, Drennan IR, et al. Defibrillation strategies for refractory ventricular fibrillation. *N Engl J Med*. 2022; 387(21): 1947–1956, doi: [10.1056/NEJMoa2207304](https://doi.org/10.1056/NEJMoa2207304), indexed in Pubmed: 36342151.
4. Emmerson AC, Whitbread M, Fothergill RT. Double sequential defibrillation therapy for out-of-hospital cardiac arrests: The London experience. *Resuscitation*. 2017; 117: 97–101, doi: [10.1016/j.resuscitation.2017.06.011](https://doi.org/10.1016/j.resuscitation.2017.06.011), indexed in Pubmed: 28624593.
5. Kim HE, Lee KJa, Jo YH, et al. Refractory ventricular fibrillation treated with double simultaneous defibrillation: pilot study. *Emerg Med Int*. 2020; 2020: 5470912, doi: [10.1155/2020/5470912](https://doi.org/10.1155/2020/5470912), indexed in Pubmed: 32566304.
6. Ross EM, Redman TT, Harper SA, et al. Dual defibrillation in out-of-hospital cardiac arrest: A retrospective cohort analysis. *Resuscitation*. 2016; 106: 14–17, doi: [10.1016/j.resuscitation.2016.06.011](https://doi.org/10.1016/j.resuscitation.2016.06.011), indexed in Pubmed: 27344928.